Stockscreener 앱 받기
30.44
0.43%
-0.13
전일 마감가:
$30.57
열려 있는:
$30.84
하루 거래량:
136.99K
Relative Volume:
0.36
시가총액:
$856.18M
수익:
$219.79M
순이익/손실:
$-57.47M
주가수익비율:
-9.0866
EPS:
-3.35
순현금흐름:
$-19.25M
1주 성능:
+6.99%
1개월 성능:
-2.96%
6개월 성능:
+24.91%
1년 성능:
+53.89%
1일 변동 폭
$30.28
$31.19
1주일 범위
$28.38
$31.23
52주 변동 폭
$16.96
$35.84
Castle Biosciences Inc Stock (CSTL) Company Profile
명칭
Castle Biosciences Inc
전화
866-788-9007
주소
505 S FRIENDSWOOD DRIVE, FRIENDSWOOD, TX
CSTL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
30.44 | 856.18M | 219.79M | -57.47M | -19.25M | -3.35 |
|
TMO
Thermo Fisher Scientific Inc
|
521.66 | 199.82B | 42.37B | 6.14B | 7.78B | 15.26 |
|
DHR
Danaher Corp
|
238.83 | 173.66B | 23.74B | 3.89B | 4.98B | 7.93 |
|
A
Agilent Technologies Inc
|
138.14 | 38.64B | 6.51B | 1.29B | 1.37B | 3.82 |
|
IQV
Iqvia Holdings Inc
|
201.43 | 36.52B | 15.32B | 1.41B | 1.96B | 5.95 |
|
IDXX
Idexx Laboratories Inc
|
421.76 | 34.55B | 3.84B | 866.24M | 792.60M | 9.80 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-01-05 | 개시 | Scotiabank | Sector Outperform |
| 2022-01-07 | 개시 | Stephens | Overweight |
| 2021-04-30 | 개시 | Lake Street | Buy |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2019-12-27 | 재확인 | Canaccord Genuity | Buy |
| 2019-08-19 | 개시 | BTIG Research | Buy |
| 2019-08-19 | 개시 | Canaccord Genuity | Buy |
| 2019-08-19 | 개시 | Robert W. Baird | Outperform |
| 2019-08-19 | 개시 | SVB Leerink | Outperform |
모두보기
Castle Biosciences Inc 주식(CSTL)의 최신 뉴스
43,894 Shares in Castle Biosciences, Inc. (NASDAQ:CSTL) Acquired by Dynamic Technology Lab Private Ltd - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Grows Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat
Gene Panel Market to Surpass USD 11.75 Billion by 2031 | SkyQuest Technology - GlobeNewswire Inc.
Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference - BioSpace
Castle Biosciences to Present at Piper Sandler Healthcare Conference in December | CSTL Stock News - StockTitan
Castle Biosciences (CSTL) Upgraded to Strong Buy: Here's Why - MSN
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year - Business Wire
Castle Biosciences (NASDAQ:CSTL) Shares Down 7.3% Following Insider Selling - MarketBeat
Castle Biosciences CEO Derek Maetzold sells $175,087 in stock - Investing.com
GSA Capital Partners LLP Takes $1.48 Million Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat
WASATCH ADVISORS LP's Strategic Reduction in Castle Biosciences Inc Holdings - GuruFocus.com
Castle Biosciences' (NASDAQ:CSTL) Performance Is Even Better Than Its Earnings Suggest - Yahoo Finance
Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Bought by Lisanti Capital Growth LLC - MarketBeat
Principal Financial Group Inc. Purchases 40,377 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat
Lake Street Capital Increases Castle Biosciences (NASDAQ:CSTL) Price Target to $40.00 - Defense World
Castle Biosciences (CSTL) Is a Great Choice for 'Trend' Investors, Here's Why - MSN
Castle Biosciences' chief commercial officer sells $124,708 in stock - Investing.com India
Castle Biosciences to Present New Data Highlighting the Clinical Performance of DecisionDx®-Melanoma and MyPath® Melanoma at the American Society of Dermatopathology 61st Annual Meeting - BioSpace
Castle Biosciences' chief commercial officer sells $124,708 in stock By Investing.com - Investing.com Canada
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Kornitzer Capital Management Inc. KS Sells 135,636 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat
Castle Biosciences Surpasses 25,000 Test Reports Delivered for its TissueCypher® Barrett’s Esophagus Test - The Bakersfield Californian
Castle Biosciences CEO Derek Maetzold sells shares worth $166,819 By Investing.com - Investing.com UK
Use of Castle Biosciences’ DecisionDx®-Melanoma Test Significantly Reduces Unnecessary SLNB Procedures, Latest Findings from Prospective, Multicenter DECIDE Study Presented at Dermato-Onco2024 - BioSpace
Castle Biosciences price target raised to $39 from $37 at Baird - Yahoo Finance
Castle Biosciences Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Castle Biosciences price target raised to $36 from $28 at KeyBanc - Yahoo Finance
Castle Biosciences director Daniel Bradbury sells $273,251 in stock - Investing.com
Castle Biosciences' chief commercial officer sells $109,709 in stock - Investing.com
Castle Biosciences director Daniel Bradbury sells $273,251 in stock By Investing.com - Investing.com UK
Castle Biosciences Inc (CSTL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Positive Earnings - GuruFocus.com
BTIG lifts Castle Biosciences target to $45 on strong Q3 growth - Investing.com Canada
KeyBanc lifts Castle Biosciences target to $36 on test growth By Investing.com - Investing.com Canada
Castle Biosciences Inc (CSTL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Castle Biosciences Inc (CSTL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance Australia
Castle Biosciences (NASDAQ:CSTL) Issues Quarterly Earnings Results, Beats Expectations By $0.14 EPS - MarketBeat
Castle Biosciences' revenue growth leads Canaccord to reaffirm $42 stock PT - Investing.com UK
Castle Biosciences (NASDAQ:CSTL) Reaches New 52-Week High After Earnings Beat - MarketBeat
Castle Biosciences (NASDAQ:CSTL) Price Target Raised to $39.00 - MarketBeat
Castle Biosciences stock target raised, outperform on strong Q3 By Investing.com - Investing.com UK
Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2024 Earnings Call Transcript - Insider Monkey
Castle Biosciences, Inc. (CSTL) Tops Q3 Earnings and Revenue Estimates - MSN
Earnings call: Castle Biosciences reports robust Q3 growth, raises guidance By Investing.com - Investing.com Canada
Castle Biosciences Reports Strong Q3 2024 Growth - TipRanks
Castle Biosciences Inc (CSTL) Reports Q3 2024 Earnings: Revenue Hits $85.8 Million, Net Income at $2.3 Million - GuruFocus.com
Castle Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Castle Biosciences Reports Third Quarter 2024 Results - StockTitan
Harbor Capital Advisors Inc. Acquires 15,200 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat
Castle Biosciences, Inc. (CSTL) Hit a 52 Week High, Can the Run Continue? - MSN
Castle Biosciences Inc (CSTL) Q3 2024 Earnings Report Preview: W - GuruFocus.com
Castle Biosciences (NASDAQ:CSTL) Trading Down 3.8%Here's Why - MarketBeat
Castle Biosciences Inc (CSTL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.43%
0.41%
자본화:
|
볼륨(24시간):